Abstract 2124P
Background
Malnutrition affects up to 75% of cancer pts and results from a combination of anorexia and metabolic dysregulation. Metabolic and nutritional abnormalities in cancer pts can lead to cachexia, a multifactorial syndrome characterized by involuntary loss of skeletal muscle mass, systemic inflammation and increased protein catabolism. Cancer cachexia negatively affects patients’ outcomes, compliance to anticancer treatments, quality of life and survival. However, risk of malnutrition and cachexia are still under recognized in cancer pts. The Prevalence of Malnutrition in Oncology (PreMiO) study revealed that 51% of pts had nutritional impairment already at the first medical oncology visit.
Methods
The retrospective, observational NUTRIONCO study included a subpopulation (n=571 pts) of the prospective, observational PREMiO study (n=1952 pts) for whom follow-up data were collected from August 2019 to October 2021 and made available in electronic case report forms at ten medical oncology sites in Italy. The clinical outcomes that were considered for the association analysis with the baseline clinical and nutritional variables were: patient’s rehospitalization, onset of treatment-related toxicity, patient’s death and disease progression.
Results
We highlighted a statistically significant association between baseline variables and patients’ death, rehospitalization, treatment toxicity and disease progression at follow-up. We found a higher overall survival probability in well-nourished general study population vs. malnourished pts (p<0.001). Patients’ stratification revealed that malnutrition decreased the survival probability in non-metastatic pts, but not in metastatic pts (p<0.001). Multivariate analysis confirmed that baseline malnutrition (p=0.004) and VAS score for appetite loss (p=0.0104), in addition to albumin <35 g/L (p<0.0001) and neutrophil/lymphocyte ratio >3 (p=0.0007), were independently associated with death of non-metastatic pts at follow-up.
Conclusions
These findings support the importance of a proactive, early management of malnutrition and cachexia in cancer pts, and in particular in non-metastatic pts, in the perspective of a substantial improvement of their clinical outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AIOM Foundantion.
Funding
Fresenius-Kabi Italy.
Disclosure
A. Frassoldati: Financial Interests, Personal, Advisory Role: Roche, Novartis, Pfizer, Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
2065P - Communication on the first medical oncology appointment: What do cancer patients want?
Presenter: Rodrigo Vicente
Session: Poster session 06
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06